Related Experiment Videos
Cardiovascular disease and osteoporosis: is there a link between lipids and bone?
John R Burnett1, Samuel D Vasikaran
1Department of Core Clinical Pathology & Biochemistry, Royal Perth Hospital, WA, Australia. john.burnett@health.wa.gov.au
Insights
Atherosclerosis and osteoporosis share links, with potential overlapping treatments. Statins and bisphosphonates, used for cardiovascular disease and osteoporosis respectively, may offer mutual benefits, warranting further clinical investigation.
Area of Science:
- Gerontology
- Cardiovascular Science
- Bone Biology
Background:
- Atherosclerotic heart disease and osteoporosis are prevalent in aging populations.
- Accumulating evidence suggests a significant link between vascular and bone diseases, notably through calcification processes.
- The precise relationship between vascular calcification and atherosclerosis pathogenesis requires further elucidation.
Purpose of the Study:
- To review recent advances in understanding bisphosphonates and statins at cellular and molecular levels.
- To examine the relationship between cardiovascular disease and osteoporosis.
- To explore the connection between lipids and bone health.
Main Methods:
- Review of recent scientific literature on bisphosphonates and statins.
- Analysis of cellular, molecular, and end-organ actions of these drug classes.
- Examination of existing clinical data regarding their effects on bone and cardiovascular health.
Main Results:
- The cellular mechanisms of statins and bisphosphonates may not be mutually exclusive.
- Early clinical data suggest statins can increase bone density.
- Preliminary findings indicate bisphosphonates may positively influence lipid profiles and atherosclerosis in vivo.
Conclusions:
- Bisphosphonates and statins show potential for overlapping therapeutic roles in managing atherosclerosis and osteoporosis.
- Further well-designed prospective studies are essential to confirm these findings.
- Future research should investigate the effects of statins on bone and bisphosphonates on cardiovascular outcomes.
Abstract:
Atherosclerotic heart disease and osteoporosis are both diseases of old age. Evidence is accumulating for a link between vascular and bone disease. Calcification is a common feature of atherosclerotic plaques, and osteoporosis is associated with both atherosclerosis and vascular calcification. However, the relationship of vascular calcification to the pathogenesis of atherosclerosis remains incompletely understood. Hormone replacement therapy has beneficial effects in the prevention of both atherosclerosis and osteoporosis. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas the statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis. We have reviewed recent advances in the knowledge of the actions of bisphosphonates and statins at the cellular, molecular and end-organ levels in order to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bones. These studies suggest that the mechanism of actions of these two classes of drugs at the cellular level may not be mutually exclusive. There are some early clinical data to complement these findings, suggesting that statins increase bone density and bisphosphonates may have a beneficial effect in vivo on plasma lipid levels and on the atherosclerotic process. Properly designed prospective studies that examine the effect of statins on bone density and fractures, as well as the effects of bisphosphonates on lipid profiles, atherosclerotic progression and cardiovascular morbidity and mortality are needed to define clearly the clinical effects and potential new roles for these agents.